Do you have COVID-19? SAB-185 is being assessed in a research study supported by the National Institutes of Health.

Learn More Here
RSS

SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

October 6, 2021
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

October 4, 2021
SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

September 28, 2021
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19

SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19

September 24, 2021
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics

Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics

September 23, 2021
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19

SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19

September 22, 2021
SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza

SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza

September 15, 2021
SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences

SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences

September 8, 2021
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants

SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants

August 11, 2021
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021

SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021

July 9, 2021
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants

SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants

July 8, 2021